Top Healthcare Companies

Ge Healthcare Technologies Inc. (GEHC) has a forecasted full-year revenue of $882B, based on 16 quarters of SEC filing data.

Revenue is driven primarily by R&D-led product development, with SG&A contributing more modestly to the top line.

[AI commentary unavailable].

Our econometric model indicates UNH’s 6.4% revenue uptick is driven by growth leverage in scale and efficiency, not just price or member gains.

In our econometric model, COR’s FY revenue growth of 9.6% sits atop an operating structure where SG&A efficiency translates into outsized revenue leverage, evidenced by SG&A ROI of $26.22 per $1 spent.

Our econometric model shows Cardinal Health is delivering meaningful top-line growth with operating leverage: SG&A elasticity is 0.89x, so SG&A expands slower than revenue, suggesting most growth comes from volume and mix rather than fatiguing selling costs.

Our econometric model shows the 9.1% YoY revenue drop is being offset more by SG&A efficiency than by member growth or pricing power—SG&A ROI of 22.77x implies growth is coming from how effectively overhead and marketing are monetized, not just volume.

Humana posted FY revenue of $144B, up 11.2% YoY, and our econometric model flags efficient SG&A as a key growth lever, with SG&A generating $3.46 in revenue per $1 spent.

Elevance Health posted 94B in revenue, up 2.7% YoY, and our econometric model suggests the lift comes from higher membership and favorable risk-adjusted Medicare Advantage revenue, not merely price hikes.

Johnson & Johnson posted FY revenue of $93B with a -0.9% YoY, signaling a stable base but no accelerating growth.

[AI commentary unavailable].

Revenue growth is driven by SG&A investments, with a 1% rise in SG&A associated with a 0.86% increase in revenue, indicating a strong ROI on selling and marketing spend.

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

Latest quarterly revenue stood at $9.866 billion.

Revenue is driven by SG&A spending, with a near-unity elasticity of 1.04% revenue for a 1% SG&A increase, as estimated by a log-log model; the latest quarterly revenue is $9.017B.

Revenue is predominantly driven by core product sales, with the latest quarterly revenue at about $8.31 billion and a 60-quarter data history underpinning the model.

[AI commentary unavailable].

Revenue growth is driven by a combination of product demand and spending efficiency, with SG&A delivering a higher revenue elasticity (0.78% per 1% increase) than R&D (0.45% per 1% increase) in a log-log model built on 70 quarters of data.

[AI commentary unavailable].

Revenue dynamics are driven by SG&A efficiency, with $1 of SG&A spending generating $3.07 in long-run revenue, and R&D data not available for this model.

Revenue growth is driven predominantly by SG&A spending, which the model ties to a 1.00 elasticity (a 1% SG&A increase yields roughly a 1% revenue gain), while R&D shows a more modest 0.26 elasticity.

[AI commentary unavailable].

Revenue is driven by a modest positive response to SG&A spending, with a 1% increase in SG&A yielding about a 0.28% rise in revenue, per the log-log model.

[AI commentary unavailable].

[AI commentary unavailable].

SG&A investments drive revenue, with an elasticity of 0.63% in revenue for every 1% change in SG&A, while R&D impact is not quantified in this dataset.

[AI commentary unavailable].

[AI commentary unavailable].

Revenue growth is driven by SG&A spending, which the log-log model shows with a positive elasticity of 0.26% in revenue for every 1% increase in SG&A (R&D data not available).

Quarterly revenue came in at $2.866 billion, with the model showing revenue is driven by SG&A and R&D spending; SG&A has the stronger elasticity at about 0.94 per 1% spend while R&D is about 0.59.

Under the model, SG&A spending is a positive driver of long-run revenue, with a ROI of about 4.78 in revenue per dollar, while R&D spending is modeled as a negative driver, subtracting roughly 7.10 in long-run revenue per dollar.

The revenue model shows SG&A spending has higher revenue elasticity than R&D, with a 1% increase in SG&A associated with a 1.22% revenue lift versus 0.80% for 1% R&D, indicating SG&A investments currently yield stronger revenue leverage.

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

Revenue is driven more by SG&A spending than R&D, with elasticity estimates of 1.10% revenue per 1% SG&A increase and 0.45% per 1% R&D increase, indicating SG&A investments deliver the larger marginal lift.

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

Revenue growth is driven by SG&A efficiency, as each dollar of SG&A spending is modeled to generate $2.46 in long-run revenue, compared with $0.75 from R&D investments.

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

For investors evaluating West Pharmaceutical Services Inc. (WST), revenue is modeled as a linear mix of spending on R&D and SG&A, with each dollar of R&D tied to a long-run revenue delta of -19.29 and each dollar of SG&A tied to +11.35.

[AI commentary unavailable].

[AI commentary unavailable].